Question explored with the scientific record
Can i replace truvada with decovy during a 28 day pep cycle alongside raltegrqvir
The short version: no study here tested swapping Truvada for Descovy inside a 28-day PEP course with raltegravir. The closest evidence says the swap is plausible, not proven.
The one study that actually tested your regimen used Truvada (FTC/TDF) plus raltegravir for 28 days in men after sexual exposure: 92% finished the course, 89% took it as prescribed, and nobody got HIV [4]. That is the evidence for the combination you are on. It is a small, non-randomized cohort, and it does not test Descovy.
What the records do show is that Descovy (FTC/TAF) holds HIV suppression as well as Truvada in people already suppressed, with less kidney and bone loss [1][3]. In a switch trial, 97% on TAF stayed suppressed versus 93% on TDF [1]. That is treatment evidence, not prevention evidence. PEP is a different question: you need drug in the tissue where exposure happened, fast. One animal study found oral TDF concentrates heavily in gut tissue [2]. Nothing here shows TAF does the same.
| Comparison | Result | Source |
|---|---|---|
| RAL+FTC/TDF, 28-day PEP completion | 92% | [4] |
| RAL+FTC/TDF, adherence | 89% | [4] |
| Switch to TAF, week 48 suppression | 97% vs 93% TDF | [1] |
| Kidney function change on TAF | +1.2 mL/min vs -3.7 on TDF | [1] |
The muscle signal matters too: 5 of 91 men on raltegravir had severe creatine kinase rises, all resolving [4]. Adding an untested backbone swap on top of that is a real, if small, unknown.
My call: this is a question for the clinician prescribing your PEP, not a self-switch. The swap is reasonable if you have kidney or bone concerns, but no retrieved study proves Descovy plus raltegravir prevents HIV after exposure. Confidence: low.
Sources used 4
-
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
This study demonstrates that switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection is non-inferior in maintaining viral suppression while improving bone mineral density and renal …
DOI: 10.1016/s1473-3099(15)00348-5 -
Compared to Subcutaneous Tenofovir, Oral Tenofovir Disoproxyl Fumarate Administration Preferentially Concentrates the Drug into Gut-Associated Lymphoid Cells in Simian Immunodeficiency Virus-Infected Macaques
In SIV-infected rhesus macaques, oral tenofovir disoproxil fumarate (TDF) loading leads to much higher intracellular TFV-DP levels in gut-associated lymphoid tissue compared with subcutaneous tenofovir (TFV), achieving similar TFV-DP levels in peripheral blood mononuclear cells …
DOI: 10.1128/aac.01095-12 -
Emtricitabine + tenofovir alafenamide for the treatment of HIV
This study reviews the efficacy and safety of tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) in HIV treatment, highlighting TAF's improved safety profile regarding renal and bone health.
DOI: 10.1080/14656566.2017.1288720 -
Raltegravir‐emtricitabine‐tenofovir as HIV nonoccupational post‐exposure prophylaxis in men who have sex with men: safety, tolerability and adherence
In a nonrandomized cohort of HIV-negative MSM, raltegravir-emtricitabine-tenofovir NPEP was well tolerated (92% completion, 89% adherence), with no HIV seroconversions, but grade 4 creatine kinase elevations occurred in 5 of 91 recipients.
DOI: 10.1111/hiv.12075